Nasdaq · Healthcare
BeOne Medicines Ltd. (ONC)
As-reported financials and recent SEC filings for BeOne Medicines Ltd., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$5.34B
Net income
$286.9M
Net margin
5.4%
Diluted EPS
$0.19
ROE
6.6%
P/E (TTM)
63.3×
Market cap
$29.04B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B |
| Gross profit | — | — | — | $1.13B | $1.01B |
| Operating income | $447.1M | $-568.2M | $-1.21B | $-1.79B | $-1.44B |
| Net income | $286.9M | $-644.8M | $-881.7M | $-2.00B | $-1.46B |
| Diluted EPS | $0.19 | $-0.47 | $-0.65 | $-1.49 | $-1.21 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-26
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →1442026-06-23
View on EDGAR →1442026-06-23
View on EDGAR →1442026-06-23
View on EDGAR →42026-06-18
View on EDGAR →Go deeper on ONC
Search BeOne Medicines Ltd.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.